Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Operating Margin (2016 - 2025)

Historic Operating Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 47.58%.

  • Ligand Pharmaceuticals' Operating Margin rose 415100.0% to 47.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.97%, marking a year-over-year increase of 176900.0%. This contributed to the annual value of 13.53% for FY2024, which is 226200.0% down from last year.
  • Ligand Pharmaceuticals' Operating Margin amounted to 47.58% in Q3 2025, which was up 415100.0% from 17.73% recorded in Q2 2025.
  • Ligand Pharmaceuticals' Operating Margin's 5-year high stood at 66.82% during Q4 2021, with a 5-year trough of 79.89% in Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Operating Margin value was 9.65% (recorded in 2024), while the average stood at 6.32%.
  • In the last 5 years, Ligand Pharmaceuticals' Operating Margin plummeted by -1067100bps in 2022 and then skyrocketed by 637200bps in 2025.
  • Ligand Pharmaceuticals' Operating Margin (Quarter) stood at 66.82% in 2021, then tumbled by -160bps to 39.89% in 2022, then soared by 70bps to 11.95% in 2023, then crashed by -88bps to 22.51% in 2024, then soared by 311bps to 47.58% in 2025.
  • Its last three reported values are 47.58% in Q3 2025, 17.73% for Q2 2025, and 79.89% during Q1 2025.